An elevated neutrophil/lymphocyte ratio is associated with poor prognosis in stage II resected colon cancer;Un índice neutrófilo/linfocito elevado se asocia a peor pronóstico en

Revista Medica de Chile

Volumn 141, Issue 5, 2013, Pages 602-608

  Urrejola, Gonzalo I ^a   Bambs, Claudia E ^a   Espinoza, Manuel A ^a   Gellona, José ^a   Zúñiga, Álvaro M ^a   Molina, María Elena ^a   Bellolio, Felipe ^a   Miguieles, Rodrigo ^a   Campbell, James M ^a   Pinedo, George A ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Colonic neoplasms; Lymphocytes; Neutrophils

Indexed keywords

AGED; ARTICLE; BLOOD; CANCER STAGING; COLON TUMOR; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LEUKOCYTE COUNT; LYMPHOCYTE; MALE; MORTALITY; MULTIVARIATE ANALYSIS; NEUTROPHIL; PROGNOSIS;

AGED; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKOCYTE COUNT; LYMPHOCYTES; MALE; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEUTROPHILS; PROGNOSIS;

EID: 84883203940     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: 10.4067/S0034-98872013000500008     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58 (2): 71-96.
2. Cancerstats 2004. Cancer research UK. Available at: http://info.cancerresearchuk.org/cancerstats/types/bowel/. Accessed July 30, 2009.
3. McArdle CS, Hole DJ. Outcome following surgery for colorectal cancer: analysis by hospital after adjustment for case-mixanddeprivation. Br J Cancer 2002; 86: 331-5.
4. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990; 264: 1444-50.
5. Association of Coloproctology of Great Britain and Ireland. Guidelines for the management of colorectal cancer. London (UK): Association of Coloproctology of Great Britain and Ireland; 2007. Available at: www.guideline.gov/summary/summary.aspx?doc_id=11331#s23. Accessed July 30, 2009.
6. National Health and Medical Research Council of Australia. Guidelines for the Prevention, Early Detection and Management of Colorectal Cancer (CRC). National Health and Medical Research Council of Australia: Canberra, 2005. Available at: www.nhmrc.gov.au/guidelines/health_guidelines.htm. Accessed July 30, 2009.
7. Morris MJ, Platell C, De Boer B, McCaul K, Lacopetta B. Population-based study of prognostic factors in stage II colon cancer. Br J Surg 2006; 93 (7): 866-71.
8. Graziano F, Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapytrials in Dukes' B colorectal cancer patients: how much evidence is enough? Ann Oncol 2003; 14: 1026-38.
9. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-545.
10. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-7.
11. Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitricoxide-dependent mechanism. Cancer Res 2000; 60: 184-90.
12. Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD. The codependence of angiogenesis and chronic inflammation. FASEB J. 1997; 11: 457-65.
13. Zahorec R. Ratio ofneutrophil to lymphocyte count is a rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 2001; 102: 5-14.
14. Duffy BK, Gurm HS, Rajagopal V, Gupta R, Ellis SG, Bhatt DL. Usefulness of an elevated neutrophil to lymphocyte ratio in predicting long term mortality after percutaneous coronary intervention. Am J Cardiol 2006; 97 (7): 993-6.
15. Halazun KJ, Aldoori A, Malik HZ, Al-Mukhtar A, Prasaid KR, Toogood GJ, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol 2008; 34: 55-60.
16. Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P Lim E. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2009; 137 (2): 425-8.
17. Walsh SR, Cook EJ, Goulder F, Justin TA Keeling NJ. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005; 91 (3): 181-4.
18. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-45.
19. Kusumanto YH, Dam WA, Hospers GA, Sluiter WJ, Dam WA, Meijer C, et al. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis 2003; 6: 283-7.
20. Tanigawa N, Amaya N, Matsumura M, Shimomatsuya T. Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma. J ClinOncol 1997; 15: 826-2.
21. Du Klos TW, Mold C. C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol Res 2004; 30: 261-77.
22. Nozoe T, Matsumata T, Sugimachi K. Preoperative elevation of serum C-reactive protein is related to impaired immunity in patients with colorectal cancer. Am J Clin Oncol 2000; 23: 263-6.
23. Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM. Prognostic value of tumor-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 1997; 182: 318-29.
24. Jass JR. Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol 1986; 39: 585-9.
25. Svennevig JL, Lunde OC, Holter J, Bjorsvik D. Lymphoid infiltration and prognosis in colorectal carcinoma. Br J Cancer 1984; 49: 375-7.
26. Okano K, Maeba T, Moroguchi A, Ishimura K, Karasawa Y, Izuishi K et al. Lymphocytic infiltration surrounding liver metastases from colorectal cancer. J Surg Oncol 2003; 82 (1): 28-33.
27. Jass JR, Love SB, Northover JM. A new prognostic classification of rectal cancer. Lancet 1987; 1 (8545): 1303-6.
28. Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 1997; 182: 318-24.
29. Canna K, McArdle PA, McMillan DC, McNIcol AM, Smith GW, McKee RF, et al. The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer 2005; 92 (4): 651-4.
30. Jemal A, Tiwari RC, Murray T Ghafoor A, Samuels A, Ward A, et al. American Cancer Society. Cancer statistics 2004. CA Cancer J Clin 2004; 54: 8-29.
31. Jessup JM, McGinnis LS, Steele GD Jr, Menk HR, Winchester DP. The National Cancer Data Base. Report on colon cancer. Cancer 1996; 78: 918-26.
32. Graziano F, Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough? Ann Oncol 2003; 14: 1026-38.
33. Morris M, Platell C, McCaul K, Millward M, van Hazel G, Bayliss E, et al. Survival rates for stage II colon cancer patients treated with or without chemotherapy in a population-based setting. Int J Colorectal Dis 2007; 22: 887-95.
34. Shinji S, Naito Z, Ishiwata T, Tanaka N, Furukawa K, Suzuki H, et al. Clinical and Biological Significance of Lymph Node Micrometastasis in Colorectal Cancer. J Nippon Med Sch 2007; 74: 77-80.
35. Santagostino A, Saggia C, Migliora P, Pavanelli MC, Forti G, Biaggi G, et al. Prospective study on prognostic significance of DNA ploidy and Ki-67 expression in colorectal cancer. J Biol Regul Homeost Agents 2007; 21 (1-2): 13-20.
36. Buglioni S, D'Agnano I, Cosimelli M, Vaselli S, DeAngelo C, Tedesco M, et al. Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: independent prognostic role of p53 and bcl-2. Int J Cancer 1999; 84 (6): 545-52.
37. Ding PR, An X, Zhang RX, Fang YJ, Li LR, Chen G, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Int J Colorectal Dis 2010; 25 (12): 1427-33.
38. Hung HY, Chen JS, Yeh CY, Changchien CR, Tang R, Hsieh PS, et al. Effect of preoperative neutrophil-lymphocyte ratio on the surgical outcomes of stage II colon cancer patients who do not receive adjuvant chemotherapy. Int J Colorectal Dis 2011; 26 (8): 1059-65.